Compare Biogen Inc (BIIB) vs SMX Security Matters plc (SMX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs SMX Security Matters plc — how do they compare? Biogen Inc trades at $188.8 (market cap $28.34B), while SMX Security Matters plc trades at $18 (market cap $17.11M). The key difference: Biogen Inc is far larger — about 1656.3× SMX Security Matters plc's market cap, and Biogen Inc is trading nearer its 52-week high, SMX Security Matters plc nearer its low. Which is the better fit depends on your goals.
| BIIB | SMX | |
|---|---|---|
Market Cap | $28.34B | $17.11M |
Sector | Health | Technology |
52-Week High | $216.63 | $295.56K |
52-Week Low | $122.68 | $12.87 |
Enterprise Value | $30.62B | $14.08M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.
The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.
SMX trades at $16.21, up 3.58% today, amid neutral technical signals and recent reverse stock splits. The company is positioning itself in the recycling technology space with its Circularity-as-a-Service platform, targeting demand from new state recycling mandates. However, financial metrics show significant challenges with negative ROE of -2,216.26% and ROA of -398.22%, indicating substantial profitability concerns despite a reasonable P/B ratio of 1.93.
The outlook remains speculative with potential upside from regulatory tailwinds in recycling verification technology, but high execution risk given current negative profitability. Investors face substantial dilution risk from recent reverse splits and need to monitor the company's ability to convert regulatory opportunities into sustainable revenue growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About SMX Security Matters plc
SMX Security Matters plc is a digital authentication and tracking technology company that uses a chemical-based, invisible marker system to trace and verify products across global supply chains. Their technology creates a 'digital twin' of physical products, used for quality control, counterfeiting prevention, and ensuring sustainability compliance from raw materials to final sale. The company's solutions are applied across various industries, including precious materials, luxury goods, and fast-moving consumer goods.
Read more on SMX →
